Our mission is to develop microbiome-based, live biotherapeutics, as well as companion diagnostics, aimed at the prevention and treatment of inflammatory diseases, beginning with asthma.
Co-founded in late 2016 by Susan Lynch (University of California at San Francisco), Nikole Kimes (Siolta, formerly UCSF) and Samir Kaul (founder, Khosla Ventures). Siolta marries powerful new science with the venture-backed start-up world to realize its vision in a streamlined fashion.
Our team boasts decades of experience with the microbiome’s role in health, augmented with expertise in business, clinical and regulatory affairs. Our foundational technology is exclusively licensed from our work at the University of California, San Francisco. Meet the full team here.